ITEM 4. CHANGES IN REGISTRANT’S CERTIFYING ACCOUNT.

Lee PharmaceuticalsITEM delivered a copy of this Form 8-K report to Caldwell, Becker, Dervin, Petrick & Co12., L.L.P.RESULTS onOF SeptemberOPERATIONS 18,AND 2003,FINANCIAL and requested that Caldwell, Becker, Dervin, Petrick & CoCONDITION., L.L.P. furnish it with a letter addressed to the Securities and Exchange Commission (the “SEC”) stating whether or not Caldwell, Becker, Dervin, Petrick & Co., L.L.P. agrees with the above statements. Attached hereto as Exhibit 16 is a copy of the letter of Caldwell, Becker, Dervin, Petrick & Co., L.L.P. to the SEC dated September 19, 2003.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 11, 2004

~~Date~~LEE ~~of Report September 18, 2003 (Date of earliest event reported)~~PHARMACEUTICALS

LEE PHARMACEUTICALS
(Exact name of registrant as specified in its character)
CALIFORNIA
(State or other jurisdiction of incorporation)
1-7335		95-2680312
(Commission File Number)		(IRS Employer Identification Number)
1444 Santa Anita Avenue, South El Monte, California		91733
(Address of principal executive offices)		(Zip Code)
(626) 442-3141
(Registrant’s telephone number, including area code)

(Exact name of registrant as specified in its charter)

California		1-7335		95-2680312
(State or other jurisdiction of Incorporation or Organization)		(Commission File No.)		(I.R.S. Employer Identification No.)

On1444 ~~September18,~~Santa ~~2003~~Anita ~~Caldwell~~Avenue, ~~Becker,~~South ~~Dervin,~~El ~~Petrick & Co.~~Monte, ~~L.L.P., the~~California ~~principal independent accountants of Lee Pharmaceuticals resigned. The Board of Directors of Lee Pharmaceuticals approved the resignation of Caldwell, Becker, Dervin, Petrick & Co., L.L.P.~~91733

~~The~~(Address ~~report~~ of ~~Caldwell,~~ ~~Becker,~~principal ~~Dervin,~~executive Petrick & Co., L.L.P. on the financial statements of Lee Pharmaceuticals for each of its fiscal years ended September 30, 2002, 2001, and 2000 contained no adverse opinions or disclaimers of opinion, and were not otherwise modified as to audit scope, or accounting principles. The reports of Caldwell, Becker, Dervin, Petrick & Co., L.L.P. on the financial statements of Lee Pharmaceuticals for each of the past three years ended September 30, 2002, 2001, and 2000 did, however, contain explanatory paragraphs describing an uncertainty about the Company’s ability to continue as a going concern.offices)

~~During~~(626) the past three years and all interim periods prior to September 18, 2003 there were no disagreements between Lee Pharmaceuticals and Caldwell, Becker, Dervin, Petrick & Co., L.L.P., whether or not resolved, on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure which, if not resolved to Caldwell, Becker, Dervin, Petrick & Co., L.L.P.’s satisfaction, would have caused it to make reference to the subject matter of the disagreements in connection with its reports for such periods.442-3141

~~During~~(Registrant’s ~~the fiscal~~telephone ~~years ended September 30~~number, ~~2002,~~including ~~2001,~~area ~~and 2000 and all subsequent interim periods to September 18, 2003, the date of resignation, none of the events specified in Regulation S-B, Item 304(a~~code)~~(1)(iv)(B) occurred.~~

LEE PHARMACEUTICALS

September 19, 2003

/s/ Ronald G. Lee

RONALD G. LEE

On ~~September 18~~February 11, ~~2003~~2004, Lee Pharmaceuticals ~~engaged~~publicly ~~George~~announced ~~Brenner,~~by ~~CPA, as its new principal~~means ~~accountant~~of toa ~~audit~~press release its ~~financial~~first ~~statements. Lee~~quarter ~~Pharmaceuticals~~ended ~~has~~December ~~not consulted with George Brenner~~31, ~~CPA,~~2003 ~~on any~~financial ~~items~~results. The ~~concerning~~full ~~the~~text ~~application~~ of ~~accounting principles to a specified transaction, the type of audit opinion that might be rendered on~~ Lee Pharmaceuticals’ ~~financial~~press ~~statements,~~release oris ~~the~~attached ~~subject~~as ~~matter~~Exhibit of99.1 aand ~~disagreement~~is incorporated ~~with~~by ~~the~~reference ~~former~~in ~~auditor~~this orItem ~~any~~12 of ~~the~~Form ~~events specified in Regulation S~~8-~~B, Item 304(a) (1)(iv)(B)~~K.

~~ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.~~SIGNATURE

~~(a)~~Pursuant ~~Financial~~to ~~Statements.~~the ~~None~~requirements ~~(b)~~of ~~Exhibits~~the ~~16.~~Securities ~~Letter~~Exchange Act of ~~September 19~~1934, the ~~2003~~registrant ofhas ~~Caldwell,~~duly ~~Becker,~~caused ~~Dervin,~~this ~~Petrick~~report &to ~~Co.,~~be Lsigned on its behalf by the undersigned thereunto duly authorized.~~L.P.~~

		LEE PHARMACEUTICALS


Date:	February 11, 2004	By:	Ronald G. Lee
			RONALD G. LEE
			PRESIDENT

~~SIGNATURE~~2

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Filing Compare · Lee Pharmaceuticals, Inc.